A problem when routinely using PDT has been the difficulty of controlling the light dose in order to expose the tumour to the right amount of light to achieve adequate treatment effect. SpectraCure has developed the IDOSE® dose planning platform for this purpose. SpectraCure’s IDOSE® software has the potential to make interstitial PDT treatment accurate, precise and safe for each patient.

In established prostate cancer care it is normal to attempt to treat the whole gland, even though the cancer tumour itself is only a minor part of the volume. The purpose of this treatment strategy is to avoid missing any part of the cancer tumour. Against this background, SpectraCure’s initial intention of treatment method was to treat the whole prostate gland with the maximum number of needles.
SpectraCure has then further developed the software IDOSE®, which has led to improved precision and the possibility to perform so called focal PDT treatment.

In focal treatment, the focus is only on treating the cancer tumour within the prostate. Focal PDT treatment requires the physician to have information about the location and size of the tumour, which can be given by, for example, MR images.

Focal PDT treatment is mainly relevant for two different categories of prostate cancer patients. One group is patients with primary prostate cancer with low risk of spreading, and the other group is patients treated with radiotherapy but who suffer recurrence.

The technology is based on long scientific research and clinical treatments with PDT at Lund University Hospital and in collaboration with other leading researchers internationally. Globally, a total of about one million PDT treatments for skin tumours are performed annually, and SpectraCure is a world leader in the development of PDT for internal tumours.



How it works

Individualised dosimetry

The light dose from each individual optical fibre is monitored in real time so that it can be adjusted during the course of treatment. Therefore, the technology can potentially reduce the risk of incomplete treatment and make the treatment outcome independent of tissue variations.


SpectraCure’s system with IDOSE® provides a targeted treatment since the PDT effect only occurs in the area where the light dose is delivered.


Damage to tissue surrounding the treatment area can potentially be minimised through the SpectraCure IDOSE® system, as it is possible to monitor and adjust the light dose from each individual optical fibre.


SpectraCure’s technology has the potential to treat internal solid tumours without the risks associated with, for example, ionising radiation.

P18 generation 2

The new generation IDOSE® system now has a design and features that are close to the design the system will have at a future launch. The technology has been fine-tuned and further developed to offer a competitive product in the future when the treatment area can be expanded with additional indications.

The new generation system is easier for hospital staff to work with and also more adaptable to the individual circumstances of patients.

Interview with Dr. Neil Fleshner

On November 21st, 2017, SpectraCure arranged a meeting where, amongst other investigators, Dr. Neil Fleshner participated. Dr. Fleshner is a professor at the Department of Urology at the University of Toronto. He is head of uro-oncology at the Princess Margaret Cancer Centre in Toronto, where the first patients in the company's clinical phase 1 study were treated.


The feedback dose control system is based on the patented and proprietary combined approach of using the same optical fibres for treatment and collecting patient-specific control information. Together with the IDOSE® system for calculating and controlling optimal treatment parameters, this represents a unique product and treatment methodology. A significant patent portfolio of seven patent families with twelve approved patents ensures many years of exclusivity in the market. 

SpectraCure’s patent strategy is to thoroughly protect the technology in the major markets such as North America, China and Europe. Patent applications are in various stages, from pending to granted. The basic patents are approved, including in the EU, the US, China and Japan. Two more patent applications are under review.